Safusidenib for glioma with an IDH1 gene change
Original title: SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a large, late stage study, but the drug is still being tested.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a drug called safusidenib in people whose glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary has an IDH1 gene change.
Who this trial is for. This study is for people with glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary that has an IDH1 gene change. It has 3 parts, and each part tests safusidenib in a different group, including tumors that came back or grew and tumors treated after surgery, radiation, or chemo.
Where it stands. The study has not reported results. It is measuring how well safusidenib works, how safe it is, and how the body handles it. In one part, some people get the drug and some get a placebo. A placebo is a pill with no medicine in it. The answers are not in yet.
What this means, and what it doesn't
What it could mean: If your glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary has an IDH1 gene change, this study may be worth asking about. Your care team can tell you if it might fit your case.
What it doesn't mean: This does not mean safusidenib is a proven treatment. A trial is a test. Doctors are still trying to learn if the drug helps. Joining a trial is not a promise that you will get better. It is not a cure.
Source: ClinicalTrials.gov, August 28, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.